Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Axogen, Inc.
Report date August 17, 2018 · Filed August 17, 2018
Section 16 reporting ended · disclosed 2018-08-17. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 18, 2017 Filed Dec 20, 2017 23:53 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 1,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015741 · edgar.xml · derivative · entry 2 Leach Kevin · CIK 0001668805 · Vice President Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 Underlying: Common Stock · 1,400 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F3 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 23:53 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 8,250 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015741 · edgar.xml · derivative · entry 1 Leach Kevin · CIK 0001668805 · Vice President Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,250 Underlying: Common Stock · 8,250 shares Expires 2027-12-18 F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 18, 2021 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| December 29, 2016 Filed Jan 3, 2017 21:43 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 45,000 | $0.00 Strike: $8.95 | $0.00 |
DisclosureSEC source: 0001179110-17-000078 · edgar.xml · derivative · entry 1 Leach Kevin · CIK 0001668805 · Vice President Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2026-12-29 F1 · derivative.exercise_date: All shares of Common Stock underlying the employee stock option will be fully vested on December 29, 2020(4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on December 29, 2017(12 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| October 07, 2016 Filed Oct 14, 2016 19:14 UTC | Axogen, Inc. AXGN · Entity 4297 | PurchaseCommon Stock | 2,000 | $7.50 | $15,000.00 |
DisclosureSEC source: 0001179110-16-030714 · edgar.xml · nonDerivative · entry 1 Leach Kevin · CIK 0001668805 · Vice President Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · shares: The reporting person purchased these shares in his individual capacity and not through any directed share or other formal program in connection with an underwritten registered public offering of the Company. On October 7, 2016, the trade date for the public offering, the closing sale price reported by NASDAQ was $9.15 per share. The public offering closed on October 13, 2016 and the closing sale price reported by NASDAQ on such date was $8.72 per share. F1 · price: The reporting person purchased these shares in his individual capacity and not through any directed share or other formal program in connection with an underwritten registered public offering of the Company. On October 7, 2016, the trade date for the public offering, the closing sale price reported by NASDAQ was $9.15 per share. The public offering closed on October 13, 2016 and the closing sale price reported by NASDAQ on such date was $8.72 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.